1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Hyloris Pharmaceuticals SA
  6. News
  7. Summary
    HYL   BE0974363955

HYLORIS PHARMACEUTICALS SA

(HYL)
  Report
Real-time Euronext Bruxelles  -  11:35 2022-08-12 am EDT
13.98 EUR   +1.90%
07/20Hyloris' Oral Mouth Rinse Shows Controlled Bleeding After Tooth Extraction in Early-stage Trial
MT
07/20Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mouth Rinse for bleeding related to dental procedures
GL
07/20Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mouth Rinse for bleeding related to dental procedures
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hyloris To Start Equity Offering To Raise $17 Million

03/31/2022 | 10:23am EDT


© MT Newswires 2022
All news about HYLORIS PHARMACEUTICALS SA
07/20Hyloris' Oral Mouth Rinse Shows Controlled Bleeding After Tooth Extraction in Early-sta..
MT
07/20Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mo..
GL
07/20Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mo..
AQ
07/20Hyloris Reports Positive Phase 1 Data for HY-004, A Proprietary Tranexamic Acid Oral Mo..
CI
07/05HYLORIS PHARMACEUTICALS SA : Crossing thresholds
CO
07/01Hyloris Provides Additional Information on U.S. FDA Review of NDA Application for the R..
GL
07/01Hyloris Provides Additional Information on U.S. FDA Review of NDA Application for the R..
AQ
07/01Hyloris Pharmaceuticals Receives US FDA Request For Additional Information On Maxigesic
MT
07/01US FDA seeks more information on Maxigesic IV® application
GL
07/01Hyloris Pharmaceuticals SA Receives Complete Response Letter from the US Food and Drug ..
CI
More news
Financials
Sales 2022 10,0 M 10,3 M 10,3 M
Net income 2022 -11,0 M -11,3 M -11,3 M
Net cash 2022 27,0 M 27,7 M 27,7 M
P/E ratio 2022 -34,1x
Yield 2022 -
Capitalization 375 M 384 M 384 M
EV / Sales 2022 34,8x
EV / Sales 2023 24,6x
Nbr of Employees 21
Free-Float 45,2%
Chart HYLORIS PHARMACEUTICALS SA
Duration : Period :
Hyloris Pharmaceuticals SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HYLORIS PHARMACEUTICALS SA
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 13,98 €
Average target price 20,25 €
Spread / Average Target 44,8%
EPS Revisions
Managers and Directors
Stijn van Rompay Chief Executive Officer & Executive Director
Jean-Luc Vandebroek Chief Financial Officer
Stefan Yee Chairman
Dietmar Aichhorn Chief Operating Officer
Marc Foidart Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HYLORIS PHARMACEUTICALS SA-19.19%384
JOHNSON & JOHNSON-3.37%434 603
ELI LILLY AND COMPANY11.53%292 730
PFIZER, INC.-15.14%281 235
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.32%252 131